CliffBio
small molecule

STENDRA

AVANAFIL

Loss of exclusivity—loss of exclusivity
CompanyVivus, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameSTENDRA
Active ingredientAVANAFIL
Strength50MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalApril 2012
Marketing statusRX

More from Vivus, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.